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Purpose: The study was carried out to evaluate the quality of artesunate tablets sold in retail and 
wholesale pharmacies in Kumasi, Ghana. In particular, the study sought to ascertain the presence or 
otherwise of counterfeit artesunate tablets in Kumasi. 
Method: Artesunate tablets were purchased from pharmacies in Kumasi for the study. The mechanical 
properties of the tablets were evaluated, namely: uniformity of weight, breaking strength, friability and 
rate of disintegration in aqueous medium. Colorimetric methods were used to determine the presence of 
artesunate and to assay the tablets. 
Result: None of the artesunate tablets sampled was found to be a counterfeit. Most of the brands had 
acceptable mechanical properties in terms of mass uniformity, hardness, friability and disintegration 
time. However, the artesunate content of the tablets was variable (47.9-99.9 %). Six (35.3 %) of the 
samples passed the International Pharmacopoeia content uniformity test (93.7-99.9 %) while 11 (64.7 
%) failed the test (47.9-89.4 %). However, only 3 (17.6 %) of the samples met the European 
Pharmacopoeia (Ph. Eur.) content requirements while 14 (82.4 %) failed to meet the requirements. 
Conclusion: The presence of substandard artesunate tablets on the Ghanaian market should alert drug 
regulatory authorities to be vigilant and continually monitor the quality of this life-saving drug. 
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INTRODUCTION 
Artesunate and other artemisinin derivatives 
such as artemether, and dihydroartemisinin 
are potent drugs which are used in the 
management of uncomplicated malaria. 
Artesunate is the most widely used of the 
artemisinin derivatives
1
. The use of any of the 
artemisinins as monotherapy has, however, 
been discouraged by the WHO to minimise 
the development of resistance to these new 
antimalarials. Instead, the WHO has since 
2001 recommended the use of artemisinin-
based combination therapy (ACT) as first line 
malaria treatment in malaria-endemic African 
countries. In Ghana, artesunate-amodiaquine 
is the ACT of choice
2
. The cure rate from 
monotherapy with artesunate and other 
artemisinin derivatives is low compared to the 
use of ACT
3
. In spite of the recommendation 
from the WHO, monotherapy with artesunate 
tablets is commonly employed in the 
management of malaria in Ghana and many 
other countries in Africa
4, 5
.  
Whether employed as monotherapy or as a 
component of ACT, artesunate plays a pivotal 
role in the global fight against malaria, hence 
there is the need to guarantee its quality and 
eliminate any form of fakery or counterfeiting. 
Already there have been several reports 
cataloguing the distribution and use of 
counterfeit and substandard artesunate 
tablets in many South-East Asian countries
6-
11
. Many African countries lack the resources 
to employ advanced techniques such as high 
performance liquid chromatography; mass 
spectrometry and Raman spectroscopy
12 
which can be used to ascertain the 
authenticity of artemisinin products in the 
market and are therefore vulnerable to 
counterfeiting and substandard drugs. Also, 
artesunate and other artemisinins, being 
generally expensive drugs, are potential 
targets of counterfeiting. As a result of the 
above factors, Africa has been cited as the 
next possible destination for counterfeit and 
substandard artemisinins
10
. Already, cases of 
counterfeit and substandard artemisinins have 
been reported in African countries such as 
Tanzania, Cameroon 
8
, Kenya and the 
Democratic Republic of Congo
16
. 
In Ghana, artesunate tablet is the commonest 
artemisinin product in the market and is 
available in various strengths from both local 
and foreign manufacturers. The quality of 
these antimalarials if not properly safeguarded 
could lead to therapeutic failure in patients 
and the development of drug resistance. The 
objective of this study was, therefore, to 
evaluate the quality of artesunate tablets 
available in community and wholesale 
pharmacies in Kumasi, Ghana. The study also 
sought to determine the existence or 
otherwise of counterfeit or fake artesunate 




Five blisterpacks each of 17 brands of 
artesunate tablets manufactured by various 
pharmaceutical companies in Ghana (5 
brands) and abroad (12 brands) were 
purchased between February and March 2006 
from different pharmacy shops located in 
Kumasi, Ghana (Table 1).  The artesunate 
tablet brands include 4 combi-packs of 
artesunate and amodiaquine and one (1) 
combi-pack of artesunate and 
sulphamethoxypyrazine/pyrimethamine. 
Artesunate powder was a gift from 
Kinapharma Ltd. (Kumasi, Ghana). All the 
artesunate tablet brands sampled had a 
remaining shelf life of at least one year at the 
time of sampling. Fast Red TR salt (1, 5- 
Naphthalene-disulfonate salt, reagent grade) 
was obtained from Acros Organics (New 
Jersey, USA). Glacial acetic acid of density 
1.048-1.051 g/ml and sodium hydroxide were 
obtained from Philip Harris Plc. (Lichfield, 
England).  
Uniformity of weight and disintegration of 
tablets 
The uniformity of weight was determined as 
the relative standard deviation of twenty 
randomly selected artesunate tablets. 
The disintegration times of six randomly 
selected tablets was determined in distilled 
water at 37 ± 0.5 °C using an Erweka tablet 
disintegration tester (Type ZT3/1, 
Heusenstamm, Germany). 
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Breaking strength and friability of tablets 
The breaking strength of ten randomly 
selected tablets was determined using a 
Schleuniger hardness tester (Schleuniger and 
Co., Switzerland). 
The friability (%) of ten randomly selected 
tablets was determined using an Erweka 
friabilator (Erweka TA20, England) operated 
at 25 rpm for 4 minutes. 
Qualitative test on artesunate tablets 
A test for the presence or absence of 
artesunate in the tablets, which was meant to 
distinguish genuine artesunate from 
counterfeit ones, was carried out using a 
colorimetric field method for the qualitative 




Assay of artesunate tablets 
Artesunate tablets were quantitatively 
analysed using a previously described and 
validated colorimetric method with minor 
modifications
1
. A number of artesunate tablets 
(2-5, depending on artesunate brand) were 
crushed into powder in a porcelain mortar with 
a pestle. Artesunate powder equivalent to 0.1 
g artesunate was weighed into a 100 ml 
volumetric flask. A quantity of 1M sodium 
hydroxide was added to the artesunate 
powder to the 40 ml mark and allowed to 
stand for 20 min to hydrolyse the drug. The 
sample was filtered with a sintered glass filter 
into a 100 ml volumetric flask and to the 
filtrate was added 40 ml of 1.1 M acetic acid, 
followed by 20 ml of 5mg/ml Fast Red TR. 
The resultant solution was allowed to stand for 
5 min to form a yellowish solution. The 
amount of artesunate in the final solutions 
formed were assayed spectrophotometrically 
(Cecil 8000 Series, Cecil Instruments, 
Cambridge, England) at 420 nm with the use 
of regression data obtained from a calibration 
plot of artesunate powder (r
2
 = 0.9941). The 
tests were repeated twice and the results 
presented are the mean of three 
determinations. The whole procedure was 




The shelf life of the artesunate tablets ranged 
from 2 to 4 years. Table 1 shows the country 
of manufacture and the mechanical properties 
of the artesunate tablets. The country of 
manufacture was indicated for all the samples, 
except for ART 1. The percentage weight 
deviation of the various brands of artesunate 
from their respective mean weights was less 
than 10%. The mean tablet weight for 25 mg, 
50 mg, 100 mg and 200 mg strength 
artesunate brands was 203.5 ± 7.45 mg (n 
=1), 287.1 ± 57.2 mg (n = 11), 309.9 ± 83.6  
mg (n = 4) and 566.2 ± 9.05 mg (n = 1), 
respectively. The breaking strength of the 
tablets ranged from 2.5-17.2 kg/cm
2
. Only 
ART 13 and ART 15 had breaking strength 
values lower than 4.0 kg/cm
2
. The percentage 
friability was lower than 1 % w/w (range: 0.04-
0.85 % w/w) for all the tablets tested. All the 
tablets disintegrated in aqueous medium in 
less than 5 minutes (range: 41 ± 1.82 - 257 ± 
13.5 s).  
Qualitative tests on all the different brands of 
artesunate tablets resulted in the formation of 
a yellowish product of varying colour intensity. 
Table 2 depicts the content of artesunate in 
the tablets. The percentage artesunate 
content ranged from 47.9 to 99.9 %. Six (35.3 
%) of the tablets had artesunate content ≥ 90 
% while eleven (64.7 %) had artesunate 
content <90 % of the label claim. On the other 
hand, three (17.6 %) of the samples had 
artesunate content ≥ 95 % while fourteen 
(82.4 %) was <95%. 
 
DISCUSSION 
The country of manufacture was indicated on 
the packaging of all the brands of artesunate 
tablets except for ART 1 where the only 
address given was that of the 
dealer/marketing agent in the United 
Kingdom. This observation makes ART 1 a 
product of doubtful quality. All the tablets 
sampled were within their shelf life at the time 
of the study. Physical examination of the 
product packaging and the artesunate tablets 
of the other brands did not give any indication 
of fakery or counterfeiting. Qualitative tests on 
the artesunate tablets using the Fast Red TR 
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dye technique also produced yellowish 
coloured products signifying the presence of 
artesunate in all the artesunate tablet brands. 
Thus, none of the tablets tested was found to 
be counterfeit. Counterfeit drugs have been 
defined by the WHO as drugs which are 
‘deliberately  and fraudulently mislabelled with 
respect to identity or source and occur with 
branded and generic products and may 
include products with the correct ingredients 
but fake packaging, with the wrong 
ingredients, without active ingredients or with 
insufficient active ingredients’
14
. Variation in 
colour intensity of the samples indicates a 
variation in the amount of artesunate 
contained in the different brands of artesunate 
tablets, signifying the possibility of 
substandard tablets. Substandard drugs have 
been defined as medicines that have been 




Most of the tablets possessed appropriate 
mechanical properties in terms of weight 
uniformity, breaking strength, friability and 
disintegration time (Table 1). The different 
brands of artesunate tablets showed 
acceptable weight uniformity with weight 
deviations less than 10 %w/w. The breaking 
strength of the tablets was ≥ 4 kg/cm
2
 except 
for ART 13 (3.4 kg/cm
2
) and ART 15 (2.5 
kg/cm
2
). Thus, ART 13 and ART 15 failed the 
breaking strength test. The breaking strength 
is used to characterise the hardness of 
tablets. Tablets with breaking strength values 
≥ 4 kg/cm
2
 have acceptable hardness. The 
friability of all the artesunate brands was <1% 
w/w and the disintegration times were less 
than 15 minutes, thus all the artesunate 
brands passed the friability and disintegration 
tests. It could thus be inferred that all the 
artesunate brands studied could withstand 
abrasion without loss of tablet integrity and 
could disintegrate readily in aqueous medium, 
especially in the gastrointestinal tract.  
Quantitative analysis using absorbance 
measurements showed 6 (35.3 %) of the 
tablets passing and 11 (64.7 %) failing the 
WHO International Pharmacopoeia 
requirement which specifies artesunate tablets 
to contain not less than 90.0 % and not more 
than 110.0 % of the amount of artesunate 
indicated on the label
15
. On the other hand, 
only 3 (17.6 %) of the samples passed the 
European Pharmacopoeia content 
specifications of 95-105 % of the active drug 
substance
17
 while 14 (82.4 %) did not meet 
 
Table 1: The country of manufacture and some mechanical properties of artesunate tablets 
 















ART 1 NI 318.8 ± 9.94 12.8 ± 2.11 0.04 193 ± 9.4 
ART 2 India 282.3 ± 3.17 17.2 ± 3.10 0.07 156 ± 12.9 
ART 3 China  272.3 ± 2.13   5.3 ± 0.58 0.31 56 ± 6.4 
ART 4 China  288.4 ± 5.41 12.1 ± 1.00 0.15 68 ± 4.7 
ART 5 Ghana  283.2 ± 6.09   7.3 ± 1.25 0.24 87 ± 3.6 
ART 6  India  343.3 ± 4.55 13.7 ± 0.61 0.08 173 ± 8.2 
ART 7  Ghana  283.2 ± 7.06   5.5 ± 0.77 0.22 139 ± 4.9 
ART 8  India  294.8 ± 3.28   5.6 ± 1.35 0.20 77 ± 3.6 
ART 9 Belgium  379.0 ± 3.55 14.9 ± 3.07 0.01 148 ± 13.4 
ART 10  Switzerland  566.2 ± 9.05 17.1 ± 2.51 0.08 132 ± 12.7 
ART 11  Ghana  397.1 ± 8.01   7.2 ± 0.53 0.85 61 ± 10.6 
ART 12  India  202.5 ± 5.50   4.7 ± 0.59 0.41 121 ± 23.9 
ART 13 India  192.5 ± 8.30   3.4 ± 0.56 0.52 44 ± 2.3 
ART 14 Belgium  372.5 ± 8.51   6.6 ± 1.28 0.44 41 ± 1.82 
ART 15 Ghana  203.5 ± 7.45   2.5 ± 0.43 0.84 58 ± 4.1 
ART 16 Ghana  286.5 ± 9.60   4.5 ± 0.39 0.57 90 ± 27.4 
ART 17 India  201.5 ± 8.50   5.0 ± 0.43 0.83 257 ± 13.5 
NI = Not indicated 
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the requirement. All the samples that failed 
the International Pharmacopoeia (90-110 %) 
or the European Pharmacopoeia (95-105 %) 
content requirements of artesunate were 
underdosed and hence were substandard. For 
instance, the two most underdosed artesunate 
samples, namely: ART 6 and ART 13 
contained a little over half (53.14 %) and less 
than half (47.90 %) of the labelled amount of 
the drug, respectively. On the whole, 
artesunate tablets manufactured in Europe 
were of higher quality than those produced in 
India, China, or Ghana.  
Even though no counterfeit artesunate tablets 
was observed in the study a greater 
proportion of the brands sampled were found 
to be of substandard quality. The use of such 
substandard artesunate tablets in treatment 
 
Table 2: The strength and content of artesunate in different brands of artesunate tablets sampled 












Ph. Int.    Ph. Eur 
ART 1 Artesunate, 50mg 35.76 
 
71.52 Fail         Fail 
ART 2 Artesunate, 50mg 44.35 
 
88.70 Fail         Fail 
ART 3 Artesunate, 50mg 32.46 
 
64.91 Fail         Fail 
ART 4 Artesunate, 50mg 38.66 
 
77.31 Fail         Fail 
ART 5 Artesunate, 50mg 46.86 
 
93.72 Pass        Fail 
ART 6  Artesunate, 50mg 26.58 
 
53.16 Fail         Fail 
ART 7  Artesunate, 50mg 47.12 
 
94.24 Pass        Fail 
ART 8  Artesunate, 50mg 36.01 
 
72.02 Fail         Fail 
ART 9 Artesunate, 100mg 99.93 
 
99.93 Pass        Pass 
ART 10  Artesunate, 200mg 199.66 
 
99.83 Pass        Pass 
ART 11  Artesunate, 50mg 32.25 
 
64.50 Fail         Fail 
ART 12  Artesunate, 50mg 44.13 
 
88.25 Fail         Fail 
ART 13* Artesunate, 50mg 
Amodiaquine, 153.1 mg 
23.95 47.90 Fail         Fail 




93.73 93.73 Pass        Fail 
ART 15* Artesunate, 25mg 
Amodiaquine, 75mg 
21.91 87.65 Fail         Fail 
ART 16* Artesunate,100mg 
Amodiaquine, 300mg 
97.18 97.18 Pass        Pass 
ART 17* Artesunate, 100mg 
Amodiaquine, 300mg 
89.38 89.38 Fail         Fail 
Ph. Int. = The International Pharmacopoeia; Ph. Eur. = The European Pharmacopoeia *Combi-packs of 
artesunate and other drugs - the results are based on analysis of only the artesunate packs 
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would result in sub-therapeutic levels of the 
drug in patients, leading to treatment failure 
and possible development of drug resistance.  
There is, therefore, the need for drug 
regulatory bodies in Ghana and other African 
countries to be vigilant and undertake routine 
assessment of the quality of artesunate and 
other artemisinin products on the market in 




No counterfeit or fake artesunate was found 
out of 17 brands of artesunate tablets 
sampled. Eleven of the samples were 
however found to be of substandard quality as 
they contained lower amounts of artesunate. 
Routine tests using the fast-red TR test (dye 
test) is invaluable in detecting counterfeit and 
substandard artesunate tablets on the market. 
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